Over the past 30 years, survival of patients with de novo metastatic cancers shows divergent trends, with substantial gains against some cancers but limited or no progress against others.
Misty Selph found herself with a rare metastatic cancer and an insurance plan that covered virtually none of the specialized care she required, forcing tough choices and delaying her care.
A study from the US Department of Defense found cancer incidence was higher among military air and ground crew in comparison with the general population, but they were not more likely to die from cancer.
Among patients with unresectable anaplastic thyroid cancer treated with lenvatinib, average survival was prolonged. The study was published as a preprint and has not yet been peer reviewed.
Variants in two gene pathways appear to be directly linked to sarcoma development. The finding offers hope for earlier cancer detection and treatment, suggest researchers.